Fetal Mesenchymal Stem Cells in Cancer Therapy

Author(s): Vasiliki Bitsika, Antonia Vlahou, Maria G. Roubelakis.

Journal Name: Current Stem Cell Research & Therapy

Volume 8 , Issue 2 , 2013

Become EABM
Become Reviewer

Abstract:

There is compelling evidence that mesenchymal stem cells (MSCs) can be utilized as delivery vehicles for cancer therapeutics. During the last decade, bone marrow MSCs have been used as delivery vehicles for the local production of therapeutic proteins in multiple tumor types, taking advantage of their innate tropism to the tumor site and their low immunogenicity. More recently, MSCs have been isolated from fetal tissues during gestation or after birth. Fetal MSCs derived from amniotic fluid, amniotic membrane, umbilical cord matrix (Wharton’s jelly) and umbilical cord blood are more advantageous than adult MSCs, as they can be isolated noninvasively in large numbers without the ethical reservations associated with embryo research. Several studies have documented that fetal MSCs harbor a therapeutic potential in cancer treatment, as they can home to the tumor site and reduce tumor burden. This natural tumor tropism together with their low immunogenicity renders fetal MSCs as powerful therapeutic tools in gene therapy-based cancer therapeutic schemes. This review summarizes various approaches where the tumor-homing capacity of fetal MSCs has been employed for the localized delivery of anti-tumor therapeutic agents.

Keywords: Anti-tumor molecules, cellular therapy, fetal stem cells, mesenchymal stem cells, tumor, cancer therapeutics, Wharton’s Jelly, Umbilical Cord Blood, Umbilical Cord, Amniotic epithelial stem cells

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 2
Year: 2013
Page: [133 - 143]
Pages: 11
DOI: 10.2174/1574888X11308020004
Price: $58

Article Metrics

PDF: 18